what are the major cryptocurrencies Top See results about

Foreign media: Trump "strongly opposes" Ukraine's use of American-made missiles to attack Russia's hinterland, and at the same time says that he will not give up Ukraine. According to Reuters's report, US President-elect Trump criticized Ukraine's use of American-made missiles to attack targets in Russia on the 12th local time, arguing that this has aggravated the escalation of the war between Russia and Ukraine. However, he also mentioned that he would not give up Ukraine. When talking about the Russian-Ukrainian conflict, Trump said in an interview, "What happened is crazy. This is crazy. I strongly object to launching missiles hundreds of miles into Russia. Why are we doing this? This will only escalate this war and make the situation worse. " According to the report, Trump hopes to end this "war" that lasted for nearly three years as soon as possible, but he is more cautious about revealing specific details. When asked if Kiev would cut its military and humanitarian aid to Ukraine if it did not agree to the peace agreement, Trump responded, "I think I have a very good plan to help Ukraine, but when I started to disclose this plan, it would almost become a worthless plan." In addition, when asked if he would give up Ukraine, Trump replied, "I hope to reach an agreement, and the only way to reach an agreement is not to give up." (World Wide Web)The negative spread of 10-year treasury bonds between China and the United States has expanded to more than 250BP, the largest since June 2002.The Japanese side hyped China's threat to return to the old road of military expansion. Recently, Japanese Prime Minister Shi Pomao delivered a policy address saying that Chinese aircraft carriers sailed in the waters close to Japan's territorial waters, and carrier-based aircraft conducted thousands of take-off and landing trainings in the Pacific Ocean; Based on the national security strategy, Japan will greatly strengthen its defense forces. In this regard, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said that the Japanese side's hype about the so-called "China military threat" was just to cover up its usual trick of getting rid of the shackles of the peaceful constitution and taking the old road of military expansion again. As a matter of fact, the diplomatic and defense departments of China and Japan have been maintaining communication on air and sea security issues. There is absolutely no need for the Japanese side to be jittery and nervous. (CCTV)

On December 4, the price of pig food was 7.74, up 0.52% from November 27. According to the data of the National Development and Reform Commission, as of December 4, the price of live pigs nationwide was 16.72 yuan/kg, down 1.30% from November 27. The price of corn in the main wholesale market is 2.16 yuan/kg, down 1.82% from November 27; The price of pig food was 7.74, up 0.52% from November 27th.Zongheng Communication established a new science and technology company in Zhejiang. The enterprise search APP shows that recently, Zongheng Cross-border Technology (Zhejiang) Co., Ltd. was established with Xu Shasha as its legal representative and a registered capital of 10 million yuan. Its business scope includes: sales of information security equipment; Network equipment sales; Internet of things technical services, etc. Enterprise equity penetration shows that the company is wholly owned by Zongheng Communication.The retail sector continued its upward trend of Zhongbai Group for 10 days and 7 boards, and the retail sector continued its upward trend. Zhongbai Group for 10 days and 7 boards, Maoye Commercial and Actually Zhijia had daily limit, and Guangbai shares, Dashang shares, Central Shopping Mall and Hongqi Chain opened higher collectively.

Zijiang Enterprise set up a packaging company in Hubei with 20 million yuan. According to the enterprise search APP, Hubei Zijiang Packaging Co., Ltd. was recently established, with Shao Chunjiang as the legal representative and a registered capital of 20 million yuan. Its business scope includes: the production of plastic packaging containers and tools for food; Sales of plastic packaging containers, tools and products for food. Enterprise investigation shows that the company is wholly owned by Zijiang Enterprise.List of stock repurchases of Hong Kong stocks: 43 stocks were repurchased by the company. On December 12, a total of 43 Hong Kong stocks were repurchased by the company, and the repurchase amount of 8 stocks exceeded HK$ 10 million. Among them, Tencent Holdings, AIA and Samsonite have the largest repurchase amounts, with the company repurchasing HK$ 704 million, HK$ 61,711,300 and HK$ 34,247,500 respectively. As of December 12, 274 Hong Kong stocks have been repurchased by the company this year, and the cumulative repurchase amount of 62 stocks during the year exceeded HK$ 100 million. Among them, Tencent Holdings, HSBC Holdings and AIA have the largest cumulative repurchase amount during the year, with the company repurchasing HK$ 104.602 billion, HK$ 40.706 billion and HK$ 31.059 billion respectively.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)